Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
Total Valuation
Mersana Therapeutics has a market cap or net worth of $36.13M. The enterprise value is -$19.93M.
Market Cap$36.13M
Enterprise Value-$19.93M
Share Statistics
Mersana Therapeutics has 4,990,692 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,990,692
Owned by Insiders17.55%
Owned by Institutions0.08%
Financial Efficiency
Mersana Therapeutics’s return on equity (ROE) is 7.28 and return on invested capital (ROIC) is -74.86%.
Return on Equity (ROE)7.28
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-74.86%
Return on Capital Employed (ROCE)-0.89
Revenue Per Employee397.03K
Profits Per Employee-678.35K
Employee Count102
Asset Turnover0.28
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Mersana Therapeutics is ―. Mersana Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value-18.43
Price to FCF―
Price to Operating Cash Flow-0.47
PEG Ratio―
Income Statement
In the last 12 months, Mersana Therapeutics had revenue of 40.50M and earned -69.19M in profits. Earnings per share was -14.12.
Revenue40.50M
Gross Profit38.87M
Operating Income-73.34M
Pretax Income-68.77M
Net Income-69.19M
EBITDA-63.27M
Earnings Per Share (EPS)-14.12
Cash Flow
In the last 12 months, operating cash flow was -79.76M and capital expenditures 0.00, giving a free cash flow of -79.76M billion.
Operating Cash Flow-79.76M
Free Cash Flow-79.76M
Free Cash Flow per Share-15.98
Dividends & Yields
Mersana Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.76
52-Week Price Change-80.13%
50-Day Moving Average7.85
200-Day Moving Average19.37
Relative Strength Index (RSI)53.41
Average Volume (3m)123.89K
Important Dates
Mersana Therapeutics upcoming earnings date is Nov 11, 2025, TBA (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend Date―
Financial Position
Mersana Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of -38.80%
Current Ratio2.19
Quick Ratio2.19
Debt to Market Cap0.13
Net Debt to EBITDA1.25
Interest Coverage Ratio-18.93
Taxes
In the past 12 months, Mersana Therapeutics has paid 418.00K in taxes.
Income Tax418.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Mersana Therapeutics EV to EBITDA ratio is -1.52, with an EV/FCF ratio of -1.16.
EV to Sales2.37
EV to EBITDA-1.52
EV to Free Cash Flow-1.16
EV to Operating Cash Flow-1.17
Balance Sheet
Mersana Therapeutics has $76.97M in cash and marketable securities with $20.62M in debt, giving a net cash position of -$56.35M billion.
Cash & Marketable Securities$76.97M
Total Debt$20.62M
Net Cash-$56.35M
Net Cash Per Share-$11.29
Tangible Book Value Per Share-$1.94
Margins
Gross margin is 91.21%, with operating margin of -181.09%, and net profit margin of -170.86%.
Gross Margin91.21%
Operating Margin-181.09%
Pretax Margin-169.82%
Net Profit Margin-170.86%
EBITDA Margin-156.24%
EBIT Margin-160.26%
Analyst Forecast
The average price target for Mersana Therapeutics is $30.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.83
Price Target Upside297.81% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast16.14%
EPS Growth Forecast31.01%